Glaxo and Xenoport Migraine Drug Fails Shares Fall

Published July 7, 2010

Glaxo and Xenoport migraine drug fails shares fall
An experimental migraine drug from GlaxoSmithKline and its partner XenoPort has failed in mid-stage trials sending the U.S. company’s shares down more than 25 percent.
Read more on Reuters via Yahoo! UK & Ireland News

Extended Anti-Clotting Drug Use May Help More Patients
A treatment plan used to prevent potentially dangerous blood clots in recovering surgical patients can also benefit some patients immobilized by acute medical illness, doctors have found in a multi-institutional study. In women, patients age 75 or older, and patients strictly confined to 24-hour bed rest, a month of extended treatment with a blood thinner significantly reduced the chances of …
Read more on Medical News Today